American Society of Clinical Oncology
American Society of Clinical Oncology - ASCO
136180380
1965
asco.org
ASCO
ASCOCancer
29100
More from
Alpha Tau Omega FraternityBrno |
|
Catholics for Tradition IncKosmonosy |
|
The New Ipswich Historical SocietyTurnov |
|
New Hope Residence for Women IncPíšťany |
|
American Federation of State County & Municipal EmployeesPardubice |
Similar traffic
National World War II Museum, Inc. |
|
Institute for the Study of War Inc |
|
350 Org |
|
Conference Board Inc |
|
Bridge Fund Grant Assistance Corporation |
Similar social media (76000)
The draft guideline protocol, Systemic Therapy for Sarcoma, is now available for open comment. Provide your feedback to us by April 17. Find more details here: https://brnw.ch/21wRM4m (fb)
The incidence of #ColorectalCancer (CRC) in people under 50 is increasing worldwide. This is in stark contrast to CRC rates overall, which are decreasing due to growing screening programs. A number of risk factors—a Westernized diet rich in processed foods and red meat, alcohol, and a sedentary lifestyle—could play a role, but the answer also may lie within the microbiome. #ASCODailyNews has more on the link between an altered, proinflammatory microbiome and the development of CRC: https://brnw.ch/21wRGVe (fb)
80 - 100
4.5
About the organization
- G30 -
Sign in or create account Search Abstracts and Presentations Discover Upcoming ASCO Meetings Benefits of an ASCO Membership Important Dates MEETING 2025 ASCO Annual Meeting May 30 Jun 04 2025 Online InPerson Chicago IL Early Registration Deadline April 23 2025 SAVE THE DATE Best of ASCO Jul 11 Jul 13 2025 Online InPerson Minneapolis MN SAVE THE DATE Quality Care Symposium Oct 10 Oct 12 2025 Online InPerson Chicago IL Most Viewed Videos Slides ASCO Plenary Series Results from the randomized phase III DREAMM7 study of belantamab mafodotin belamaf bortezomib and dexamethasone BVd vs daratumumab bortezomib and dexamethasone DVd in relapsedrefractory multiple myeloma RRMM. First Author MariaVictoria Mateos PhD Abstract 2025 ASCO Genitourinary Cancers Symposium Mevrometostat PF06821497 an enhancer of zeste homolog 2 EZH2 inhibitor in combination with enzalutamide in patients with metastatic castrationresistant prostate cancer mCRPC A randomized doseexpansion study. First Author Michael Schweizer Poster 2022 ASCO Annual Meeting Time to response duration of response and patientreported outcomes PROs with daratumumab DARA plus lenalidomide and dexamethasone DRd versus lenalidomide and dexamethasone Rd alone in transplantineligible patients with newly diagnosed multiple myeloma NDMM Subgroup analysis of the phase 3 MAIA study. First Author Thierry Facon Journal Journal of Clinical Oncology ASCO Ethical Guidance for the US Oncology Community Where Reproductive Health Care Is Limited by Law First Author Rebecca A.
Cancer
